Bone engineering by phosphorylated-pullulan and β-TCP composite

Tomohiro Takahata, Takumi Okihara, Yasuhiro Yoshida, Kumiko Yoshihara, Yasuyuki Shiozaki, Aki Yoshida, Kentaro Yamane, Noriyuki Watanabe, Masahide Yoshimura, Mariko Nakamura, Masao Irie, Bart Van Meerbeek, Masato Tanaka, Toshifumi Ozaki, Akihiro Matsukawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A multifunctional biomaterial with the capacity bond to hard tissues, such as bones and teeth, is a real need for medical and dental applications in tissue engineering and regenerative medicine. Recently, we created phosphorylated-pullulan (PPL), capable of binding to hydroxyapatite in bones and teeth. In the present study, we employed PPL as a novel biocompatible material for bone engineering. First, an in vitro evaluation of the mechanical properties of PPL demonstrated both PPL and PPL/β-TCP composites have higher shear bond strength than materials in current clinical use, including polymethylmethacrylate (PMMA) cement and α-tricalcium phosphate (TCP) cement, Biopex-R. Further, the compressive strength of PPL/β-TCP composite was significantly higher than Biopex-R. Next, in vivo osteoconductivity of PPL/β-TCP composite was investigated in a murine intramedular injection model. Bone formation was observed 5 weeks after injection of PPL/β-TCP composite, which was even more evident at 8 weeks; whereas, no bone formation was detected after injection of PPL alone. We then applied PPL/β-TCP composite to a rabbit ulnar bone defect model and observed bone formation comparable to that induced by Biopex-R. Implantation of PPL/β-TCP composite induced new bone formation at 4 weeks, which was remarkably evident at 8 weeks. In contrast, Biopex-R remained isolated from the surrounding bone at 8 weeks. In a pig vertebral bone defect model, defects treated with PPL/β-TCP composite were almost completely replaced by new bone; whereas, PPL alone failed to induce bone formation. Collectively, our results suggest PPL/β-TCP composite may be useful for bone engineering.

Original languageEnglish
Article number065009
JournalBiomedical Materials (Bristol)
Volume10
Issue number6
DOIs
Publication statusPublished - Nov 20 2015

Fingerprint

Bone
Phosphates
Composite materials
Biocompatible Materials
Biomaterials
tricalcium phosphate
pullulan
Defects
Cements
Bond strength (materials)
Polymethyl Methacrylate
Hydroxyapatite
Tissue engineering
Durapatite
Compressive strength
Tissue
Mechanical properties
Biopex

Keywords

  • bone formation
  • phosphorylated-pullulan
  • β-TCP

ASJC Scopus subject areas

  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

Bone engineering by phosphorylated-pullulan and β-TCP composite. / Takahata, Tomohiro; Okihara, Takumi; Yoshida, Yasuhiro; Yoshihara, Kumiko; Shiozaki, Yasuyuki; Yoshida, Aki; Yamane, Kentaro; Watanabe, Noriyuki; Yoshimura, Masahide; Nakamura, Mariko; Irie, Masao; Van Meerbeek, Bart; Tanaka, Masato; Ozaki, Toshifumi; Matsukawa, Akihiro.

In: Biomedical Materials (Bristol), Vol. 10, No. 6, 065009, 20.11.2015.

Research output: Contribution to journalArticle

Takahata, T, Okihara, T, Yoshida, Y, Yoshihara, K, Shiozaki, Y, Yoshida, A, Yamane, K, Watanabe, N, Yoshimura, M, Nakamura, M, Irie, M, Van Meerbeek, B, Tanaka, M, Ozaki, T & Matsukawa, A 2015, 'Bone engineering by phosphorylated-pullulan and β-TCP composite', Biomedical Materials (Bristol), vol. 10, no. 6, 065009. https://doi.org/10.1088/1748-6041/10/6/065009
Takahata, Tomohiro ; Okihara, Takumi ; Yoshida, Yasuhiro ; Yoshihara, Kumiko ; Shiozaki, Yasuyuki ; Yoshida, Aki ; Yamane, Kentaro ; Watanabe, Noriyuki ; Yoshimura, Masahide ; Nakamura, Mariko ; Irie, Masao ; Van Meerbeek, Bart ; Tanaka, Masato ; Ozaki, Toshifumi ; Matsukawa, Akihiro. / Bone engineering by phosphorylated-pullulan and β-TCP composite. In: Biomedical Materials (Bristol). 2015 ; Vol. 10, No. 6.
@article{41f0f9985d75408682f5d2c182af2b7a,
title = "Bone engineering by phosphorylated-pullulan and β-TCP composite",
abstract = "A multifunctional biomaterial with the capacity bond to hard tissues, such as bones and teeth, is a real need for medical and dental applications in tissue engineering and regenerative medicine. Recently, we created phosphorylated-pullulan (PPL), capable of binding to hydroxyapatite in bones and teeth. In the present study, we employed PPL as a novel biocompatible material for bone engineering. First, an in vitro evaluation of the mechanical properties of PPL demonstrated both PPL and PPL/β-TCP composites have higher shear bond strength than materials in current clinical use, including polymethylmethacrylate (PMMA) cement and α-tricalcium phosphate (TCP) cement, Biopex-R. Further, the compressive strength of PPL/β-TCP composite was significantly higher than Biopex-R. Next, in vivo osteoconductivity of PPL/β-TCP composite was investigated in a murine intramedular injection model. Bone formation was observed 5 weeks after injection of PPL/β-TCP composite, which was even more evident at 8 weeks; whereas, no bone formation was detected after injection of PPL alone. We then applied PPL/β-TCP composite to a rabbit ulnar bone defect model and observed bone formation comparable to that induced by Biopex-R. Implantation of PPL/β-TCP composite induced new bone formation at 4 weeks, which was remarkably evident at 8 weeks. In contrast, Biopex-R remained isolated from the surrounding bone at 8 weeks. In a pig vertebral bone defect model, defects treated with PPL/β-TCP composite were almost completely replaced by new bone; whereas, PPL alone failed to induce bone formation. Collectively, our results suggest PPL/β-TCP composite may be useful for bone engineering.",
keywords = "bone formation, phosphorylated-pullulan, β-TCP",
author = "Tomohiro Takahata and Takumi Okihara and Yasuhiro Yoshida and Kumiko Yoshihara and Yasuyuki Shiozaki and Aki Yoshida and Kentaro Yamane and Noriyuki Watanabe and Masahide Yoshimura and Mariko Nakamura and Masao Irie and {Van Meerbeek}, Bart and Masato Tanaka and Toshifumi Ozaki and Akihiro Matsukawa",
year = "2015",
month = "11",
day = "20",
doi = "10.1088/1748-6041/10/6/065009",
language = "English",
volume = "10",
journal = "Biomedical Materials",
issn = "1748-6041",
publisher = "IOP Publishing Ltd.",
number = "6",

}

TY - JOUR

T1 - Bone engineering by phosphorylated-pullulan and β-TCP composite

AU - Takahata, Tomohiro

AU - Okihara, Takumi

AU - Yoshida, Yasuhiro

AU - Yoshihara, Kumiko

AU - Shiozaki, Yasuyuki

AU - Yoshida, Aki

AU - Yamane, Kentaro

AU - Watanabe, Noriyuki

AU - Yoshimura, Masahide

AU - Nakamura, Mariko

AU - Irie, Masao

AU - Van Meerbeek, Bart

AU - Tanaka, Masato

AU - Ozaki, Toshifumi

AU - Matsukawa, Akihiro

PY - 2015/11/20

Y1 - 2015/11/20

N2 - A multifunctional biomaterial with the capacity bond to hard tissues, such as bones and teeth, is a real need for medical and dental applications in tissue engineering and regenerative medicine. Recently, we created phosphorylated-pullulan (PPL), capable of binding to hydroxyapatite in bones and teeth. In the present study, we employed PPL as a novel biocompatible material for bone engineering. First, an in vitro evaluation of the mechanical properties of PPL demonstrated both PPL and PPL/β-TCP composites have higher shear bond strength than materials in current clinical use, including polymethylmethacrylate (PMMA) cement and α-tricalcium phosphate (TCP) cement, Biopex-R. Further, the compressive strength of PPL/β-TCP composite was significantly higher than Biopex-R. Next, in vivo osteoconductivity of PPL/β-TCP composite was investigated in a murine intramedular injection model. Bone formation was observed 5 weeks after injection of PPL/β-TCP composite, which was even more evident at 8 weeks; whereas, no bone formation was detected after injection of PPL alone. We then applied PPL/β-TCP composite to a rabbit ulnar bone defect model and observed bone formation comparable to that induced by Biopex-R. Implantation of PPL/β-TCP composite induced new bone formation at 4 weeks, which was remarkably evident at 8 weeks. In contrast, Biopex-R remained isolated from the surrounding bone at 8 weeks. In a pig vertebral bone defect model, defects treated with PPL/β-TCP composite were almost completely replaced by new bone; whereas, PPL alone failed to induce bone formation. Collectively, our results suggest PPL/β-TCP composite may be useful for bone engineering.

AB - A multifunctional biomaterial with the capacity bond to hard tissues, such as bones and teeth, is a real need for medical and dental applications in tissue engineering and regenerative medicine. Recently, we created phosphorylated-pullulan (PPL), capable of binding to hydroxyapatite in bones and teeth. In the present study, we employed PPL as a novel biocompatible material for bone engineering. First, an in vitro evaluation of the mechanical properties of PPL demonstrated both PPL and PPL/β-TCP composites have higher shear bond strength than materials in current clinical use, including polymethylmethacrylate (PMMA) cement and α-tricalcium phosphate (TCP) cement, Biopex-R. Further, the compressive strength of PPL/β-TCP composite was significantly higher than Biopex-R. Next, in vivo osteoconductivity of PPL/β-TCP composite was investigated in a murine intramedular injection model. Bone formation was observed 5 weeks after injection of PPL/β-TCP composite, which was even more evident at 8 weeks; whereas, no bone formation was detected after injection of PPL alone. We then applied PPL/β-TCP composite to a rabbit ulnar bone defect model and observed bone formation comparable to that induced by Biopex-R. Implantation of PPL/β-TCP composite induced new bone formation at 4 weeks, which was remarkably evident at 8 weeks. In contrast, Biopex-R remained isolated from the surrounding bone at 8 weeks. In a pig vertebral bone defect model, defects treated with PPL/β-TCP composite were almost completely replaced by new bone; whereas, PPL alone failed to induce bone formation. Collectively, our results suggest PPL/β-TCP composite may be useful for bone engineering.

KW - bone formation

KW - phosphorylated-pullulan

KW - β-TCP

UR - http://www.scopus.com/inward/record.url?scp=84950129925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950129925&partnerID=8YFLogxK

U2 - 10.1088/1748-6041/10/6/065009

DO - 10.1088/1748-6041/10/6/065009

M3 - Article

C2 - 26586655

AN - SCOPUS:84950129925

VL - 10

JO - Biomedical Materials

JF - Biomedical Materials

SN - 1748-6041

IS - 6

M1 - 065009

ER -